| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697293 | Bulletin du Cancer | 2017 | 5 Pages |
Abstract
Since the first edition of the 2012-2013 Clinical Practice Recommendations Nice-Saint-Paul for gynecological cancers, the management of ovarian cancer has become more complex with a better definition of histological subtypes of ovarian cancers, the update of the anatomo-clinical classifications, the evolution of the recommended quality criteria for surgery. In addition, the integration of new medical options, such as PARP inhibitors, requires us to review our management of ovarian cnacer patients (including early systematic oncogenetic research of homologous recombination pathway deficiency). Similarly, medical treatment has evolved in advanced cervical cancer with the new option of bévacizumab therapy. On behalf of the GINECO group, we have updated the guidelines for ovarian epithelial cancer (excepted rare tumors) and advanced cervical cancer in order to allow rapid dissemination of the latest advances to the medical community in order to adjust the daily practice.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Florence Joly, Denis Querleu, Moise Namer, Eric Pujade-Lauraine,